[go: up one dir, main page]

PE20180034A1 - Composiciones farmaceuticas para terapias combinadas - Google Patents

Composiciones farmaceuticas para terapias combinadas

Info

Publication number
PE20180034A1
PE20180034A1 PE2017001987A PE2017001987A PE20180034A1 PE 20180034 A1 PE20180034 A1 PE 20180034A1 PE 2017001987 A PE2017001987 A PE 2017001987A PE 2017001987 A PE2017001987 A PE 2017001987A PE 20180034 A1 PE20180034 A1 PE 20180034A1
Authority
PE
Peru
Prior art keywords
insulin
disease
reduction
insulin secretion
insulin sensitivity
Prior art date
Application number
PE2017001987A
Other languages
English (en)
Inventor
Mark Pruzanski
Luciano Adorini
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of PE20180034A1 publication Critical patent/PE20180034A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composicion farmaceutica que comprende un agonista del FXR y por lo menos un agente terapeutico adicional que reduce el nivel de glucosa en sangre, estimula la secrecion de insulina y/o aumenta la sensibilidad a la insulina. Dicho agente adicional es una sulfonilurea, un mimetico de incretina, un inhibidor de la dipeptidil peptidasa-4, una bigaunida, un secuestrante de acidos biliares, entre otros. La composicion es util para el tratamiento o la prevencion de una enfermedad o condicion mediada por FXR, como por ejemplo NAFLD y NASH, una enfermedad o condicion relacionada con un nivel elevado de glucosa en sangre, una la reduccion de la secrecion de insulina y/o la reduccion de la sensibilidad a la insulina, tal como hiperglucemia, diabetes, obesidad y resistencia a la insulina, o para disminuir el nivel de glucosa en sangre, estimular la secrecion de insulina y/o aumentar la sensibilidad a la insulina
PE2017001987A 2015-04-07 2016-04-06 Composiciones farmaceuticas para terapias combinadas PE20180034A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562144040P 2015-04-07 2015-04-07

Publications (1)

Publication Number Publication Date
PE20180034A1 true PE20180034A1 (es) 2018-01-09

Family

ID=57072872

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001987A PE20180034A1 (es) 2015-04-07 2016-04-06 Composiciones farmaceuticas para terapias combinadas

Country Status (25)

Country Link
US (1) US10894054B2 (es)
EP (1) EP3280421B1 (es)
JP (1) JP6879931B2 (es)
KR (1) KR20170132879A (es)
CN (1) CN107613986A (es)
AR (1) AR104195A1 (es)
AU (1) AU2016246524B2 (es)
BR (1) BR112017021311A2 (es)
CA (1) CA2981507A1 (es)
CL (2) CL2017002538A1 (es)
CO (1) CO2017010292A2 (es)
CR (1) CR20170456A (es)
EA (1) EA036757B1 (es)
EC (1) ECSP17073004A (es)
ES (1) ES2974281T3 (es)
IL (2) IL254772A0 (es)
MA (1) MA41083A1 (es)
MX (1) MX2017012893A (es)
NI (1) NI201700121A (es)
PE (1) PE20180034A1 (es)
SM (1) SMT202400104T1 (es)
SV (1) SV2017005539A (es)
TN (1) TN2017000426A1 (es)
TW (1) TW201642869A (es)
WO (1) WO2016164413A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
KR20180006881A (ko) 2015-03-09 2018-01-19 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
WO2017182873A2 (en) 2016-04-19 2017-10-26 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
CN116790476A (zh) 2016-05-05 2023-09-22 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
EP3534907A4 (en) * 2016-11-04 2020-06-24 Children's Hospital Medical Center COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
WO2019074793A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
KR20210002573A (ko) * 2018-04-24 2021-01-08 주식회사 피에이치파마 간 질환에 호중구 엘라스타제 저해제의 사용
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US12428622B2 (en) 2018-09-12 2025-09-30 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
WO2020081766A1 (en) * 2018-10-18 2020-04-23 Avolynt Use of sglt2 inhibitors to treat primary sclerosing cholangitis
AU2019384074B2 (en) 2018-11-20 2025-04-10 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
WO2020108830A1 (en) * 2018-11-30 2020-06-04 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
WO2020198383A1 (en) * 2019-03-26 2020-10-01 Intercept Pharmaceuticals, Inc. Methods of diagnosis and treatment of liver diseases using obeticholic acid
WO2020205024A1 (en) * 2019-04-04 2020-10-08 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
AU2020283048A1 (en) 2019-05-31 2021-12-23 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
US12497597B2 (en) 2019-05-31 2025-12-16 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
WO2021029656A1 (ko) * 2019-08-14 2021-02-18 주식회사 바이오톡스텍 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
MX2023008364A (es) * 2021-01-14 2023-07-26 Enyo Pharma Metodo para el tratamiento de enfermedades renales cronicas.
WO2023225507A1 (en) * 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
AU2023273030A1 (en) 2022-05-16 2024-11-07 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
AU2023284453A1 (en) * 2022-06-08 2024-12-19 Kojin Therapeutics, Inc. Methods and compositions for initiating, regulating, and modulating weight loss and therapeutic applications thereof
CN120789063A (zh) * 2025-08-15 2025-10-17 北京大学第三医院（北京大学第三临床医学院） 一种药物组合物、制剂及其制备方法和应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
US6639078B1 (en) 1998-12-23 2003-10-28 Smithkline Beecham Corporation Assays for ligands for nuclear receptors
US6465258B1 (en) 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
TR200102805T2 (tr) 1999-03-29 2002-04-22 F.Hoffmann-La Roche Ag Glikokinaz aktivatörleri
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
US7138390B2 (en) 2001-03-12 2006-11-21 Intercept Pharmaceuticals Steroids as agonists for FXR
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
AU2003228485A1 (en) 2002-04-12 2003-10-27 The University Of Chicago Farnesoid x-activated receptor agonists
WO2005012318A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica Nv Substituted fused heterocyclic c-glycosides
EA010655B1 (ru) 2003-08-01 2008-10-30 Янссен Фармацевтика Н.В. Замещенные индазол-о-глюкозиды
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
SI1734970T1 (sl) 2004-03-12 2015-04-30 Intercept Pharmaceuticals, Inc. Zdravljenje fibroze z uporabo FXR ligandov
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US8389472B2 (en) 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
LT2347762T (lt) * 2005-08-19 2019-08-26 Amylin Pharmaceuticals, Llc Eksendinas, skirtas diabeto gydymui ir kūno svorio mažinimui
JP5081161B2 (ja) * 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
BRPI0712262A2 (pt) 2006-05-24 2012-07-10 Lilly Co Eli agonistas de fxr
DE602007005256D1 (de) 2006-05-24 2010-04-22 Lilly Co Eli Verbindungen und verfahren zur modulierung von fx-rezeptoren
WO2008002573A2 (en) 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
WO2008073825A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. Lxr and fxr modulators
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
US20100056546A1 (en) 2008-09-04 2010-03-04 Auspex Pharmaceuticals, Inc. Sulfonylurea inhibitors of atp-sensitive potassium channels
CN102639125A (zh) * 2009-05-27 2012-08-15 百时美施贵宝公司 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CN107266681A (zh) 2010-02-24 2017-10-20 瑞立普萨公司 用作胆汁酸螯合剂的胺聚合物
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
US9775556B2 (en) 2010-05-26 2017-10-03 Andre′ A. DiMino Apparatus and method for uroflowmetry
KR20130101057A (ko) 2010-09-15 2013-09-12 스미토모 덴키 고교 가부시키가이샤 레이저 가공 방법
WO2012106581A1 (en) 2011-02-03 2012-08-09 The University Of Chicago Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction
SG11201408501UA (en) 2012-06-19 2015-01-29 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
PT2997035T (pt) 2013-05-14 2018-07-18 Intercept Pharmaceuticals Inc Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e seus conjugados de aminoácido como moduladores do recetor farnesoide x
TN2017000344A1 (en) * 2015-02-06 2019-01-16 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy

Also Published As

Publication number Publication date
JP6879931B2 (ja) 2021-06-02
CN107613986A (zh) 2018-01-19
NI201700121A (es) 2018-01-10
JP2018510900A (ja) 2018-04-19
SV2017005539A (es) 2019-01-18
AU2016246524A1 (en) 2017-10-26
BR112017021311A2 (pt) 2018-06-26
CL2017002538A1 (es) 2018-04-20
IL268316A (en) 2019-09-26
EA036757B1 (ru) 2020-12-17
CR20170456A (es) 2018-06-13
US10894054B2 (en) 2021-01-19
TW201642869A (zh) 2016-12-16
AU2016246524B2 (en) 2021-04-01
AR104195A1 (es) 2017-07-05
IL254772A0 (en) 2017-12-31
WO2016164413A1 (en) 2016-10-13
MX2017012893A (es) 2018-01-15
MA41083A1 (fr) 2018-05-31
EA201792203A1 (ru) 2018-02-28
IL268316B (en) 2022-02-01
EP3280421B1 (en) 2023-12-27
TN2017000426A1 (en) 2019-04-12
EP3280421A1 (en) 2018-02-14
CL2018001007A1 (es) 2018-06-15
SMT202400104T1 (it) 2024-05-14
US20180117065A1 (en) 2018-05-03
ES2974281T3 (es) 2024-06-26
CO2017010292A2 (es) 2018-01-05
ECSP17073004A (es) 2018-02-28
CA2981507A1 (en) 2016-10-13
KR20170132879A (ko) 2017-12-04
EP3280421A4 (en) 2019-08-28

Similar Documents

Publication Publication Date Title
PE20180034A1 (es) Composiciones farmaceuticas para terapias combinadas
EA201590759A1 (ru) Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина
EA201790568A1 (ru) Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени
CL2019001115A1 (es) Formulación líquida de un conjugado de insulina de acción prolongada. (divisional solicitud 201500177).
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
MX382408B (es) Coagonistas de los receptores de glucagón y de glp-1.
CL2013003547A1 (es) Peptido derivado de oxintomodulina; polinucleotido que lo codifica; composicion farmaceutica que lo comprende; uso del peptido para tratar la obesidad.
CL2016003069A1 (es) Composición para tratar la diabetes mellitus, que comprende conjugados de variantes de insulina humana y una región fc, y además comprende un conjugado compuesto por un agonista doble de glp-/glucagón y una región fc
CR9220A (es) Terapia combinatoria para el tratamiento de la diabetes y de condiciones relacionadas con la misma o para el tratamiento de condiciones mejoradas aumentando un nivel de glp-1 en sangre.
UY33700A (es) ?combinaciones farmacéuticas para el tratamiento de trastornos metabólicos?.
BR112016023039A2 (pt) agonistas duplos dos receptores de glp-1 / glucagon derivados de exendina-4
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
MX387086B (es) Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
EA201691420A1 (ru) Композиции енолазы 1 (eno1) и их применение
EA201591123A1 (ru) Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств
CL2019000625A1 (es) Combinación de agonistas de fxr.
MX377386B (es) Compuesto que tiene actividad agonística de gpr119, método para preparar el mismo y composición farmacéutica que incluye el mismo como componente efectivo.
CL2020000207A1 (es) Agonistas del receptor de prostaciclina para la reducción de la grasa corporal.
EA201401133A1 (ru) Фармацевтическая композиция для профилактики и лечения нарушений, связанных с избыточным весом или ожирением (варианты), наборы (варианты), их применение и способ профилактики и лечения нарушений, связанных с избыточным весом или ожирением